{
    "nctId": "NCT00090857",
    "briefTitle": "Letrozole in Preventing Breast Cancer in Postmenopausal Women",
    "officialTitle": "A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Change in Lumbar Density From Baseline to 12 Months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* At increased risk for the development or recurrence of breast cancer, defined as an estradiol level \u2265 9 pg/mL\n* No evidence of suspicious or malignant disease, based on the following examinations:\n\n  * Clinical bilateral breast examination within the past 6 months\n  * Bilateral\\* mammogram within 3 months before randomization OR within 30 days after randomization\n  * Pelvic exam normal within the past 5 years\n  * General physical exam within the past 6 months NOTE: \\*Unilateral mammogram of the uninvolved breast for patients with prior invasive breast cancer or ductal carcinoma in situ (DCIS)\n* Bone density scan within 2 standard deviations from normal within the past 30 days\n\n  * Bone density scan \u2265 2 standard deviations below normal allowed if approved by the study physician\n* At least 1 breast that has not been previously treated with radiotherapy or surgery (for patients with prior invasive breast cancer or DCIS)\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 35 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined by any of the following criteria:\n\n  * At least 12 months without spontaneous menstrual bleeding\n  * Prior hysterectomy and bilateral salpingo-oophorectomy\n  * \u2265 55 years of age with a prior hysterectomy with or without oophorectomy\n  * \\< 55 years of age with a prior hysterectomy without oophorectomy OR the status of the ovaries is unknown AND follicle-stimulating hormone (FSH) level is in the postmenopausal range\n\nPerformance status\n\n* Normal activity must not be restricted for a significant portion of the day\n\nLife expectancy\n\n* At least 10 years\n\nHematopoietic\n\n* Complete blood count with differential normal\n\n  * Prior benign neutropenia allowed provided the granulocyte count is \u2265 1,500/mm\\^3\n\nHepatic\n\n* Bilirubin normal\n* Alkaline phosphatase normal\n* SGOT and SGPT normal\n\nRenal\n\n* Creatinine normal\n\nCardiovascular\n\n* No uncontrolled cardiovascular disease\n\nOther\n\n* Not pregnant\n* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No osteoporosis\n* No hyperlipidemia\n* No mental health status resulting in cognitive or emotional impairment that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* More than 30 days since prior AND no concurrent use of any of the following hormonal agents:\n\n  * Estrogen or progesterone replacement therapy\n  * Oral contraceptives\n  * Raloxifene or other plasma estrogen receptor modulators (SERMs)\n  * Androgens (e.g., danazol)\n  * Luteinizing hormone-releasing hormone (LHRH) analogs (e.g., goserelin or leuprolide)\n  * Prolactin inhibitors (e.g., bromocriptine)\n  * Antiandrogens (e.g., cyproterone)\n* More than 60 days since prior AND no concurrent tamoxifen\n* No prior aromatase inhibitors (for patients with prior invasive breast cancer or DCIS)\n* No concurrent phytoestrogenic dietary supplements (e.g., soy, ginseng, or other natural products)\n\n  * Dietary soy allowed\n\nRadiotherapy\n\n* See Disease Characteristics\n\nSurgery\n\n* See Disease Characteristics\n* No prior bilateral mastectomy\n\nOther\n\n* More than 60 days since prior treatment for invasive breast cancer or DCIS\n* More than 30 days since prior bisphosphonates or calcitonin\n* No prior or concurrent participation on a treatment study for invasive breast cancer or DCIS\n* No concurrent participation in any other cancer prevention study or osteoporosis prevention study involving pharmacologic agents\n* No concurrent calcitonin\n* No concurrent bisphosphonate therapy\n* Concurrent cholecalciferol (vitamin D) and calcium to augment bone mineral density allowed",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}